← Leaderboards
John Eikelboom
Duke University
$346,768
Attributed
$1,387,070
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $776.8K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,387,070 · 1
By mechanism
U24$1,387,070 · 1
Top collaborators
- Shrikant I Bangdiwala3 shared
- Jackie Bosch3 shared
- Sreekanth Vemulapalli3 shared
Most similar at Duke University
Same institution · by research overlap
- Daniel B Mark$29,174,449
- Richard Clinton Becker$11,111,515
- Alisa S Wolberg$13,659,847
- Karen P Alexander$27,753,285
- Sean M O'Brien$12,883,796
Others in their field
Other Rising Stars on “Adherence”
- Dennis Eyler · Fisher Bioservices, Inc.$16,341,540
- Matthew Morrow Engelhard · Duke University$7,519,665
- Andrew Gardiner · Libero Pharma Limited$6,351,015
- Richard Schrock · Fisher Bioservices, Inc.$5,879,422
- Christopher J. Lindsell · Vanderbilt University Medical Center$5,384,363
- Charles Daniel Meyers · Tempero Bio, Inc.$5,310,920
Research focus
AdherenceAcuteAmputationAnti-Inflammatory AgentsAdvocateBlood Pressure MonitorsBlood VesselsCanadaCardiovascular SystemCessation Of LifeChronicClinical CareClinical DataClinical ResearchClinical TrialsClinical Trials Data Monitoring CommitteesClinical Trials DesignColchicineCollaborationsCollectionCompanionsCoronary Heart DiseaseCost EffectivenessC-Reactive Protein
Grant awards (3)
2/2 Low dose colchicine in pAtients with peripheral artery DiseasE to assess residual vascular risk (LEADER-PAD)$656,265
U24 · FY2025 · HL
2/2 Low dose colchicine in pAtients with peripheral artery DiseasE to assess residual vascular risk (LEADER-PAD)$120,557
U24 · FY2025 · HL
2/2 Low dose colchicine in pAtients with peripheral artery DiseasE to assess residual vascular risk (LEADER-PAD)$610,248
U24 · FY2024 · HL